Metagenomi Revenue and Competitors
Estimated Revenue & Valuation
- Metagenomi's estimated annual revenue is currently $55.8M per year.
- Metagenomi's estimated revenue per employee is $218,824
- Metagenomi's total funding is $277M.
Employee Data
- Metagenomi has 255 Employees.
- Metagenomi grew their employee count by 33% last year.
Metagenomi Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $1.1M | 5 | 0% | N/A | N/A |
#4 | $2.3M | 12 | 9% | N/A | N/A |
#5 | $1.4M | 8 | -20% | N/A | N/A |
#6 | N/A | 7 | 40% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.5M | 12 | 9% | N/A | N/A |
What Is Metagenomi?
Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.
keywords:N/A
$277M
Total Funding
255
Number of Employees
$55.8M
Revenue (est)
33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Metagenomi's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Cell therapy | Reveal Email/Phone |
2 | Sr. Director, Process Engineering & Manufacturing | Reveal Email/Phone |
3 | Scientist I, Cell Therapy | Reveal Email/Phone |
4 | Director, Novel Delivery Technologies for Genetic Medicines | Reveal Email/Phone |
5 | Associate Scientist | Reveal Email/Phone |
6 | Senior Associate, Quality Control | Reveal Email/Phone |
7 | Principal Scientist | Reveal Email/Phone |
8 | Accounting Manager | Reveal Email/Phone |
9 | Head Information Technology | Reveal Email/Phone |
10 | Corporate Controller | Reveal Email/Phone |
Metagenomi News
Metagenomi, a biotech startup that three months ago struck a research alliance with Moderna, has raised $175 million to expand and build on...
Metagenomi, a genetic medicines company with an assortment of next-generation gene editing tools, has announced the completion of an...
Metagenomi, an Emeryville, Calif.-based gene editing company, extended and closed its Series A financing, bringing the round to a total of $75m. The round was led by RA Capital Management, which joined the Series A investor syndicate, including co-lead investors Leaps by Bayer and Humboldt Fund ...
Sofia, Metagenomi, Strava, Elevation Oncology among the companies landing fresh capital Adaptilens: Adaptilens is a Boston-based maker of an injectable lens for improving vision. Adaptilens has raised $1.6 million in seed funding led by Pillar VC. Read more Sofia: Sofia is a Mexico-based healt ...
California - Metagenomi, a next generation gene editing company launched by UC Berkeley scientists in 2018, successfully completed a USD 65 million Series A financing round and emerged from stealth mode today. The Series A round was led by Leaps by Bayer and Humboldt Fund. Other investors inclu ...
Other Companies in Emeryville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $77.6M | 269 | 7% | N/A |
#2 | $72.2M | 321 | N/A | N/A |
#3 | $76.5M | 340 | N/A | N/A |
#4 | $87.6M | 362 | 5% | N/A |
#5 | $79.1M | 372 | N/A | N/A |
Metagenomi Executives
| Name | Title |
|---|---|
| Alan Cohen | CMO & SVP of Monogenic Diseases |
| Simren Delaney | VP of Legal & Chief of Staff |
| Brian Thomas | CEO and Founder |
| Jian Irish | President & COO |
| Simon Harnest | Chief Investment Officer and SVP of Strategy |
| Alan Cohen | CMO & SVP of Monogenic Diseases |
| Gregory Cost | Vice President of Biology |
| Lindsay Caldwell | Vice President Human Resources |
| Simren Delaney | VP of Legal & Chief of Staff |
| Alan Brooks | VP Pre-Clinical Research |
| Jian Irish | President & COO |
| Simon Harnest | Chief Investment Officer and SVP of Strategy |